Antibody Engineering Company F-Star Buys Back Royalty Obligations
TVM Capital Joins Investor Syndicate
f-star announced that it has acquired future royalty obligations to New Century Pharmaceuticals (NCP) via a one-off payment.
Modular Antibody Technology was originally developed by Prof. Florian Rueker, one of f-star's founders, in collaboration with NCP, a U.S. biopharmaceutical company. After f-star's foundation, NCP became one of the Company's common shareholders and had rights to future royalty payments. In the course of the transaction, f-star has now bought back these royalty obligations and TVM Capital, a transatlantic venture capital firm based in Munich and Boston, acquired NCP's minority stake in f-star.
"We are very pleased that our technology is now essentially free of royalty obligations," Gottfried Himmler, CEO of f-star, commented on the transaction. "And we are delighted to have TVM Capital, one of the leading life science investors in Europe, joining f-star's strong international investor syndicate."
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.